EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas

Amy Jamieson iD, Melissa K McConechy iD, Amy Lum iD, Janine Senz iD, Tanner Dowhy iD, David G Huntsman iD, Jessica N McAlpine iD

Journal of Gynecologic Oncology · 2025

DOI: 10.3802/jgo.2025.36.e5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2025. Verfasst von Amy Jamieson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Endometrial Neoplasms, Ovarian Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Cancer Research Society, BC Cancer Foundation, Vancouver General Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Biomarkers reflecting real-time response to therapy and recurrence are lacking. We assessed the clinical value of detecting cell-free circulating tumor DNA (ctDNA) mutations in endometrial cancer (EC) and ovarian cancer (OC) patients. METHODS: EC/OC patients undergoing primary surgery were consented for tissue banking and 2-year serial blood draws. Tumor tissue DNA and plasma ctDNA underwent next generation sequencing using a targeted gene panel for somatic mutations. RESULTS: Of 44 patients (24 EC, 17 OC, 2 synchronous endometrial and ovarian carcinomas [SEOC] and 1 endocervical adenocarcinoma [EA]) at least one somatic mutation was identified in tumor tissue in 40 (91%, 20/24 EC, all OC/SEOC/EA), and in preoperative plasma ctDNA in 12 (27%) patients (6/24 [25%] EC and 6/17 [35%] OC). Detection of preoperative ctDNA mutations was associated with advanced stage, higher preoperative CA125, and subsequent disease recurrence. In 5/12 (42%) patients with preoperative ctDNA mutations, examination/imaging suggested clinical stage I however final pathology revealed stage II/III. In 11 patients where serial timepoints were assessed during treatment for ctDNA and CA125, ctDNA clearance preceded normalization of CA125. Thirteen patients developed recurrent disease (4 EC, 8 OC, 1 EA); 8 in whom ctDNA mutations were detected postoperatively, and 4 followed through time of recurrence with ctDNA mutations identified 2-5 months prior to clinical/radiologic/biomarker progression in 3. CONCLUSION: ctDNA can reflect larger tumor volume/metastases, treatment response and subsequent disease recurrence in EC and OC. Careful patient selection is critical to direct resources to patients most likely to benefit, considering disease burden and risk group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAEndometrial NeoplasmsOvarian NeoplasmsHumansFemaleMiddle AgedAgedMutationBiomarkers, TumorAdultAged, 80 and overNeoplasm Recurrence, LocalCA-125 AntigenHigh-Throughput Nucleotide SequencingNeoplasm Staging

Stichwörter der Autor:innen

Circulating Tumor DNAEndometrial CancerMutationsOvarian Cancer

Substanzen

Circulating Tumor DNABiomarkers, TumorCA-125 Antigen

Autor:innen und Institutionen

  • Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of British Columbia, Vancouver, Canada.
  • Imagia Canexia Health, Inc., Vancouver, Canada.
  • Department of Molecular Oncology, University of British Columbia, Vancouver, Canada.
  • Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of British Columbia, Vancouver, Canada. jessica.mcalpine@vch.ca.

ORCID-Profile: Amy Jamieson, Melissa K McConechy, Amy Lum, Janine Senz, Tanner Dowhy, David G Huntsman, Jessica N McAlpine

Förderung

  • Canadian Cancer Research Society
  • BC Cancer Foundation
  • Vancouver General Hospital Foundation
  • VCHRI
  • Chew Wei Memorial Chair in Gynecologic Oncology
  • Miller-Mindell Fellowship
  • Vancouver Coastal Health Research Institute

Zitieren

APA

Jamieson, A., McConechy, M. K., Lum, A., Senz, J., Dowhy, T., Huntsman, D. G., & McAlpine, J. N. (2025). Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2025.36.e5

Vancouver

Jamieson A, McConechy MK, Lum A, Senz J, Dowhy T, Huntsman DG, et al. Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas. Journal of Gynecologic Oncology. 2025. doi:10.3802/jgo.2025.36.e5

BibTeX
@article{Jamieson2025,
  author = {Jamieson, Amy and McConechy, Melissa K and Lum, Amy and Senz, Janine and Dowhy, Tanner and Huntsman, David G and McAlpine, Jessica N},
  title = {Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas},
  journal = {Journal of Gynecologic Oncology},
  year = {2025},
  doi = {10.3802/jgo.2025.36.e5}
}
Kostenlos starten →